Current Report Filing (8-k)
22 October 2019 - 7:21AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 15, 2019
RELMADA
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
|
001-39082
|
|
45-5401931
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File
Number)
|
|
(IRS Employer
Identification No.)
|
|
880
Third Avenue, 12th Floor
New
York, NY
|
|
10022
|
|
(Address of principal
executive offices)
|
|
(Zip Code)
|
Registrant’s
telephone number, including area code (212) 547-9591
|
|
|
(Former name or former
address, if changed since last report)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
|
☐
|
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class
|
|
Trading Symbol
|
|
Name
of exchange on which registered
|
|
Common
stock, $0.001 par value per share
|
|
RLMD
|
|
The
NASDAQ Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
7.01 Regulation FD Disclosure.
On
October 15, 2019, Relmada Therapeutics, Inc. (the “Company”) hosted a conference call to discuss top-line data from
its double-blind, placebo-controlled Phase 2 clinical study evaluating the safety, tolerability and efficacy of REL-1017 (dextromethadone)
as an adjunctive treatment in patients with treatment resistant depression (the “REL-1017 Phase 2 Results”). A live
webcast of the conference call was, and a replay is, available online from the News and Events—Company Events page of the
Company’s corporate website at www.relmada.com. In connection with the conference call, the Company utilized a slide presentation
(the “REL-1017 Phase 2 Presentation”). A copy of the REL-1017 Phase 2 Presentation is attached as Exhibit 99.1 to
this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference.
The
information in this Item 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is being
furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933,
as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 8.01.
Other Events
On
October 15, 2019, the Company issued a press release in which it reported the REL-1017 Phase 2 Results. A copy of the press release
is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated into this Item 8.01 by reference.
Item
9.01. Financial Statements and Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Dated: October 21, 2019
|
RELMADA THERAPEUTICS, INC.
|
|
|
|
|
|
|
By:
|
/s/
Sergio Traversa
|
|
|
Name:
|
Sergio Traversa
|
|
|
Title:
|
Chief Executive
Officer
|
2